Introduction
Breast cancer (BC) is a highly heterogeneous disease that includes ERα + , HER2 + , and triple-negative forms (TNBC; ERα -, progesterone receptor [PR] -, and HER2 -). 1 TNBC can be further divided into several different subtypes, including basal-like and claudin-low/mesenchymal-like BC. 2 Cell lines established from these tumors are referred to as Basal-A and Basal-B, respectively. These cell lines resemble the BCs from which they were derived and can be used as surrogates for primary tumors. 3 Patients affected by TNBC are currently treated with single agent or combination therapies of doxorubicin, paclitaxel, 5-fluorouracil, epirubicin, methotrexate, cyclophosphamide, cisplatin, and gemcitabine. [4] [5] [6] [7] [8] [9] [10] [11] [12] Although effective, most combinations have adverse side effects, including neutropenia, neuropathy, and cardiotoxicity, and many tumors still progress to metastasis. 4, 9 Regimes with a more tolerable toxicity tend to yield a much lower overall response rate. 10, 11 There is, therefore, a great need to improve efficacy of existing combination therapies by mitigating toxic side effects and improving complete response rates. One way of achieving this is through discovery of new drugs, either as single-agent treatments or in combination with existing regimes. Here we performed a high-throughput drug screen against human TNBC cells to identify novel therapeutics and identified disulfiram, an FDA-approved drug used to treat alcoholism, as the most potent growth inhibitor.
triple-negative breast cancer (tNBC) represents an aggressive subtype, for which radiation and chemotherapy are the only options. Here we describe the identification of disulfiram, an FDA-approved drug used to treat alcoholism, as well as the related compound thiram, as the most potent growth inhibitors following high-throughput screens of 3185 compounds against multiple tNBC cell lines. the average IC 50 for disulfiram was ~300 nM. Drug affinity responsive target stability (DARtS) analysis identified IQ motif-containing factors IQGAp1 and MYH9 as direct binding targets of disulfiram. Indeed, knockdown of these factors reduced, though did not completely abolish, cell growth. Combination treatment with 4 different drugs commonly used to treat tNBC revealed that disulfiram synergizes most effectively with doxorubicin to inhibit cell growth of tNBC cells. Disulfiram and doxorubicin cooperated to induce cell death as well as cellular senescence, and targeted the eSA + /CD24 -/low /CD44 + cancer stem cell population. our results suggest that disulfiram may be repurposed to treat tNBC in combination with doxorubicin.
Results

High-throughput drug screening identifies disulfiram as an effective growth inhibitor of TNBC cells
To discover novel therapeutics for TNBC, we performed a robotic-assisted high-throughput screen of 4 different TNBC cell lines with 3185 small molecules, including 2000 and 1185 compounds from the Spectrum and Prestwick libraries, respectively. These partially overlapping libraries consist of FDA-approved drugs and additional agents with known biological activity. The 4 cell lines used in our screens (HCC70, MDA-MB-231, MDA-MB-436, and Bt549) represent a wide range of TNBCs with respect to pRb and p53 tumor suppressors status as well as subtype (basal-like and claudin-low). Each screen and validation of hits was performed in 384-well format, using alamar blue viability assay readout. Tables S1 and  S2 ). Among the most potent compounds were known antineoplastic agents such as doxorubicin. In addition, a small number of compounds not previously known to target TNBC were identified, including disulfiram (DSF) and its structurally related analog thiram ( Fig. 1C and D) .
Dose-response curves for DSF and a number of top hits were performed on all 4 TNBC lines. DSF was more effective against each cell line than doxorubicin, daunorubicin, mitoxantrone, colchicine, or paclitaxel ( Fig. 1E-J) . Notably, MDA-MB-436 cells were resistant to the mitotic inhibitors colchicine and paclitaxel but highly susceptible to DSF. To further test for efficacy of DSF against TNBC, we performed MTT viability assays on a panel of 13 human-derived TNBC lines ( Fig. 2A and B) . Both DSF and thiram effectively suppressed growth of TNBC cells, with an average IC 50 across all lines of 300 nM and 360 nM, respectively. The effect of these drugs was similar for both Basal-A and Basal-B TNBC cell lines ( Fig. 2C and D) .
Identification of IQGAP1 scaffold protein and myosin heavy chain 9 as binding targets for disulfiram
Thiram, a sulfur fungicide applied directly to the skin for treatment of scabies, is moderately toxic by ingestion and highly toxic when inhaled. 13 Disulfiram (DSF) is used to treat alcoholism based on its inhibitory effect on acetaldehyde dehydrogenases, which are encoded by 3 of the 19 different aldehyde dehydrogenase (ALDH) genes, ALDH1A1, ALDH2, and ALDH1B1/ ALDH5. It has mild side effects in humans that include headache, metallic taste, and drowsiness due to increased production of tryptophol in the liver. 14, 15 Beyond treatment of alcoholism, disulfiram was found in non-biased drug screens to show antineoplastic activity against prostate cancer and glioblastoma [16] [17] [18] and is the subject of ongoing clinical trials for lung and liver cancer. 19, 20 DSF has been implicated in multi-drug resistance, NFkB-mediated apoptosis, phosphoinositide 3-kinase signaling, and induction of p53. [21] [22] [23] [24] ALDH1A3 is commonly elevated in cancer stem cells (CSC). 25 However, this isoform is not expressed in MDA-MB-231 cells, 26 in which we showed DSF to have a potent inhibitory effect ( Figs. 1 and 2) . Thus, it is unlikely that DSF exerts its effects through ALDH1A3.
To identify targets of DSF, we performed Drug Affinity Responsive Target Stability (DARTS) analysis [27] [28] [29] using MDA-MB-231 cells treated with 100 nM DSF. Cell lysates were incubated with varying concentrations of DSF before digestion with pronase followed by SDS-PAGE and silver staining (Fig. 3A) . DSF-protected bands were identified, extracted, and subject to mass spectrometry. Remarkably, this analysis identified 2 IQ motif-containing factors as candidate targets for DSF: IQ motif containing GTPase activating protein 1 (IQGAP1) and myosin heavy chain 9 (MYH9) (Fig. 3B-C) .
IQGAP1 is a ubiquitously expressed scaffold protein involved in cytoskeletal organization, cellular adhesion, and cell cycle regulation. [30] [31] [32] [33] [34] MYH9 is a subunit of myosin IIA that plays a role in cell motility, cell shape, and cytokinesis. [35] [36] [37] Both proteins contain IQ calmodulin-binding motifs, a highly basic α-helical sequence of ~20-25 amino acids. 38 To investigate these targets, we used Dharmacon RNA interference (RNAi, Thermo Scientific Dharmacon) in MDA-MB-231 cells. Western blot analysis confirmed near-complete or efficient knockdown of IQGAP1 and MYH9, respectively ( Fig. 3D and E) . Knockdown of each factor resulted in a 25-30% inhibition of cell growth 72 h posttransfection (Fig. 3F) . In contrast, DSF inhibited cell growth by 75% at 250 nM, 72 h post-treatment. Combined knockdown of both proteins did not consistently enhance growth inhibition (Fig. S1) . Thus, while IQGAP1 and MYH9 interact with DSF, additional factors, possibly other IQ-motif containing proteins, likely interact with and contribute to the global effect of DSF. Notably, the partial effect seen here with IQGAP1 knockdown in MDA-MB-231 tumor cells is in stark contrast to a recent paper showing that IQGAP1 inhibition suppresses tumor initiation/hyperproliferation driven by RAS signaling activation 39 (see "Discussion").
Pathway analysis reveals divergent effects of disulfiram on cellular signaling
To identify the global effects of disulfiram on cellular signaling, MDA-MB-231 cells were treated with vehicle alone, 100 nM or 250 nM DSF. After 72 h, RNA was extracted and subjected to transcriptional profiling, followed by analysis via Database for Annotation, Visualization and Integrated Discovery (DAVID), and the results were finally visualized by "functional enrichment maps". 40 This analysis revealed that DSF affected multiple signaling pathways (Fig. 4) . Upregulated pathways included antisurvival genes such as PTEN and caspases. 41, 42 Also upregulated were sphingolipids and their receptor EDG1/S1P1 pathways, which promote apoptosis as well as autophagy and cellular senescence.
43-48
Disulfiram synergizes with doxorubicin to inhibit growth of TNBC cells
We next asked whether DSF could cooperate with other drugs commonly used to treat TNBC. Specifically, we tested the combined effect of DSF plus doxorubicin, gemcitabine, paclitaxel, or the CDK4/6 inhibitor PD-0332991 ( Fig. 5;  Fig. S2 ). The most effective combination in MDA-MB-231 cells was DSF plus doxorubicin, and a synergistic response of these 2 drugs was observed across a range of concentrations (Fig. 5A) . Additional analysis revealed that the effect of DSF plus doxorubicin on MDA-MB-468, Hs578t, and HCC38 cells was additive, while the effect on HCC70 cells was synergistic ( Fig. 5B) (See "Materials and Methods" for criteria).
As doxorubicin is highly toxic, the additive/synergistic effect observed here with DSF may allow for lower doses and better clinical outcome. 
Disulfiram cooperates with doxorubicin to induce apoptosis and senescence in MDA-MB-231 cells and target the CSC fraction
Next, we sought to determine the mechanism by which DSF inhibits growth of TNBC cells. The pathway analysis revealed activation of pathways associated with cell death and senescence. Following doxorubicin and/or DSF treatment, many MDA-MB-231 cells died and lifted off the plate. The remaining population, including supernatant, was collected and subject to flow cytometry with Annexin-V and 7-AAD for early apoptotic (7-AAD -/Annexin-V + ), late apoptotic/dead (7-AAD + / Annexin-V + ), or necrotic (Annexin-V -/7-AAD + ) cells. These results demonstrated cooperation between DSF and doxorubicin in inducing cell death (38% 72 h post-treatment, Fig. 6A ). However, interestingly, the level of cell death and relative ratio of these populations was not altered dramatically, suggesting that while some cells undergo apoptosis, others are growth inhibited through additional mechanisms. This is consistent with the fact that MDA-MB-231 cells express a high level of mutant p53, which is stabilized by and contributes to survival signals generated by elevated phospholipase D in these cells. 49 Indeed, we noticed that treatment with both drugs induces enlarged cell morphology in MDA-MB-231 cells. This prompted us to test for cellular senescence through senescence-associated β-galactosidase staining. Interestingly, we found that doxorubicin or DSF treatment cultures showed X-gal-positive cells (29.9% and 23.0%, respectively), and that doxorubicin plus DSF treatment resulted in an additive effect (42.4%) (Fig. 6B-F) . We note that doxorubicin did not induce robust senescence in MDA-MB-231 as it did in MCF7 cells (Fig. 6G) , the latter of which express wild-type p53 that drives cellular senescence. 50, 51 However, doxorubicin clearly induced large, X-gal-positive MDA-MB-231 cells compared with untreated cells (Fig. 6C and D) , and combination of doxorubicin plus DSF further increased the percentage of these cells (Fig. 6F) . Thus, DSF potentiates the effects of doxorubicin on both viability and proliferation.
Cancer stem cells (CSCs) sustain tumorigenesis and exhibit distinct gene expression profiles and sensitivity to drug treatment compared with non-CSCs. [52] [53] [54] [55] CSCs in TNBC cell lines were identified by flow cytometry as ESA + /CD24 -/low /CD44 + . 56, 57 To determine the effect of DSF and doxorubicin on CSCs, MDA-MB-231 cells were treated with each drug alone or in combination. After 72 h, remaining live cells were analyzed by flow cytometry for CD24, ESA, and CD44 cell surface markers. We found that DSF and doxorubicin effectively abrogated the CSC population when used in combination (65% inhibition), as compared with treatment with DSF (5% inhibition) or doxorubicin (57% inhibition) alone (Fig. 7) . Taken together, these results suggest that DSF cooperates with doxorubicin to target TNBC cells and diminish the CSC population.
Discussion
Here, we describe identification of disulfiram (DSF) through a high-throughput screen of 3185 drugs as a potent growth inhibitor of TNBC. DSF compared favorably with several other drugs with anti-neoplastic activity, such as colchicine, paclitaxel, daunorubicin, and doxorubicin, and cooperated with the latter, which is used as mono-therapy for TNBCs, to suppress cell growth and reduce the CSC fraction. In addition, we used a non-biased target identification approach to discover IQ motifcontaining proteins as novel DSF targets.
DARTS assay identified proteins containing IQ-motifs as targets of DSF
Using the DARTS method, [27] [28] [29] we identified and confirmed IQGAP1 and myosin heavy-chain 9 (MYH9) as direct binding targets of DSF. IQGAP1 is a ubiquitously expressed scaffold protein involved in regulation of the actin cytoskeleton, transcription, cellular adhesion, and the cell cycle. [30] [31] [32] [33] [34] Recent studies suggest a role for IQGAP1 in several human cancers, such as thyroid, colorectal, gastric, and breast cancer, where it acts to modulate oncogenic pathways. [58] [59] [60] [61] [62] [63] [64] IQGAP1 interacts with at least 90 proteins and behaves as a control hub for mTOR, ERK-MAPK, and Wnt/b-catenin pathways. 30, [64] [65] [66] The IQGAP family includes IQGAP1-3, of which IQGAP2 has also been implicated in cancer. [67] [68] [69] However, neither homolog is expressed ubiquitously. IQGAP2 is expressed at highest levels in liver, kidney, and platelets, 70, 71 while IQGAP3 is predominately expressed in brain tissue, where it promotes neurite growth. 72 MYH9 is a myosin IIA heavy chain that also contains an IQ motif. MYH9 plays a role in cytokinesis, cell motility, and maintenance of cell shape. [35] [36] [37] Furthermore, myosin heavy chain 9 has been implicated in cancer metastasis [73] [74] [75] and regulation of EGFR-cytoskeletal interaction. 76, 77 Binding of DSF with these proteins is consistent with our pathway analysis, which identified divergent signaling pathways affected by DSF treatment.
Although RAS is not commonly mutated in TNBC, protooncogene tyrosine kinases are generally activated in TNBC, perhaps due to loss of the PTPN12 phosphatase. 78 Moreover, MDA-MB-231 cells have oncogenic (G13D) mutation in K-RAS. 79 Interestingly, it was recently suggested that IQGAP1 might offer a new approach to inhibit RAS-RAF-MEK-ERK signaling. Specifically, IQGAP1 knockout or knockdown inhibited initiation of tumors or hyperproliferation driven by oncogenic RAS pathway activation. 80 In contrast, we found that RNAi-mediated knockdown of IQGAP1 in MDA-MB-231 cells only accounted for partial inhibition when compared with DSF-treated cells. The discrepancy between the 2 studies may be reconciled by the fact that Jameson et al. 80 tested the effect of IQGAP1 on tumor initiation, whereas we tested the effect of knocking down IQGAP1 on pre-existing tumor cells.
We found that combined knockdown of IQGAP1 plus MYH9 did not lead to additive growth inhibition. Incomplete knockdown of MYH9 alone may account for the fractional decrease in cell viability observed. Nonetheless, this suggests that DSF exerts its effect through additional targets, possibly other IQGAP and MYH9 family members or other IQ motif-containing factors. Importantly, our results demonstrate that DSF has a stronger inhibitory effect than IQGAP1 (+/− MYH9) knockdown.
DSF cooperates with doxorubicin to decrease cell viability, increase cell death and cellular senescence, and target CSCs in TNBC
We found DSF to cooperate with doxorubicin, paclitaxel, gemcitabine, and PD-0332991 to suppress TNBC cell growth; the most potent combination was with doxorubicin. The latter is used in the treatment of TNBC. [81] [82] [83] While highly toxic to tumor cells, doxorubicin also has strong side effects against normal cells, in particular high cardiotoxicity. 84, 85 Therefore, combinatorial drug treatments with doxorubicin that can further increase its efficacy or reduce the concentration of drug required for achieving complete response would be highly beneficial in the clinic. This is particularly compelling for elderly patients with pre-existing cardiac complications. We showed that a DSF/doxorubicin combination increased apoptotic cell death and cellular senescence and diminished the CSC fraction more so than each drug alone. 
Materials and Methods
Cell lines and cultures
MDA-MB-231, MDA-MB-468, MDA-MB-157, Hs578T, and MCF7 were maintained in DMEM containing 10% FBS and 1% PEST. MDA-MB-436 was maintained in DMEM containing 10% FBS, 1% PEST, and 10 μg/ml insulin. HCC70, HCC1937, HCC38, HCC1954, HCC1569, HCC3153, and Bt549 were maintained in RPMI containing 10% FBS and 1% PEST. SUM149PT was maintained in Ham F-12 containing 5% FBS, 1% PEST, 5 μg/ml insulin, and 1 μg/ml hydrocortisone. All cell culture was grown at 37 °C with 5% CO 2 in attachment plates. Cell lines Bt549, MDA-MB-436, MDA-MB-468, MDA-MB-231, and HCC1569 were kind gifts from Dr Mona Gauthier. HCC3153 was a gift from Dr Tak Mak lab. SUM149PT was a gift from Dr Benjamin Neel Lab (Asterand). The remaining breast cancer cell lines were purchased from the America Type Culture Collection (ATCC).
Western blotting MDA-MB-231 cells were cultured in 6-well dishes with DMEM containing 10% FBS and 1% PEST and were treated 24 h after seeding at optimal density. Cells were treated with 0.25% trypsin (Sigma), washed with PBS, pelleted, and lysed with lysis buffer (0.15 M NaCl, 1% Triton X-100, 5 mM EDTA, 5 mM NaF, 0.5 mM Na 3 VO 4 , and 1:100 protease inhibitor cocktail [1 mg/mL leupeptin, 2 μg/mL aprotinin, and 100 mM PMSF]). Protein concentration was determined by a Nanodrop 1000 Spectrophotometer (Thermo Scientific). Proteins in total cell lysates were fractionated by SDS-PAGE and transferred onto nitrocellulose membranes using electrophoresis for subsequent immunoblotting. Membranes were blocked with 5% nonfat dried milk in phosphate-buffered saline containing 0.05% Tween 20 (PBST) at R.T. for 1 h. After washing the membranes 3 × 5 min with PBST, they were incubated at 4 °C overnight with rabbit anti-human IQGAP1 primary antibody (Cell Signaling), rabbit anti-human MYH9 primary antibody (Proteintech Group), or rabbit anti-tubulin primary antibody (Cell Signaling). Membranes were washed with PBST buffer 3 × 5 min each and incubated with HRP-conjugated anti-rabbit IgG secondary antibody (Cell Signaling) for 1 h. After further washing, the membranes were allowed to react with ECL (enhanced chemiluminescence substrate, Thermo Scientific); the signal was detected using autoradiography film and developed using a Konica SRX-101A developer. Primary antibodies were diluted 1:1000 in PBS (tubulin was diluted 1:2000) with 5% BSA; secondary antibody was diluted 1:2000 in PBS with 5% nonfat dried milk.
Drug screening Screens were performed in the S.M.A.R.T. Facility of the Samuel Lunenfeld Research Institute. All libraries were prepared in 100% DMSO to facilitate drug delivery via pinning. The final concentration of DMSO in each screen was 0.4%. The breast cancer lines MDA-MB-231, MDA-MB-436, Bt549, and HCC70 were seeded with their corresponding medias in 384-well plates at a density of 900 cells/well in a total volume of 50 μL/well. The following day, plates were pinned with drug libraries to reach a final concentration of 1 μM (Spectrum library, MicroSource Discovery Systems) or 0.8 μM (Prestwick library, Prestwick Chemical). Alamar blue (Invitrogen) was added 3 d post-drug pinning at 10% of the volume (5 μL/well), and cell viability was read 4-6 h later using a Pherastar plate reader. Screen data were normalized using the B-score approach to select statistically relevant hits after correction for positional effects and general systemic errors during 72 h of incubation.
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MTT viability assays Cells were seeded in 96-well plates at their optimal density (2-5 × 10 3 cells/well) and treated the following day, leaving 100 μL final volume of media. Three days (72 h) post-treatment, 30 μL of 2 mg/mL MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide, Sigma) was added to each well and incubated for 2-4 h, depending on cell type. MTT/media solution was aspirated and replaced with 100 μL DMSO and left at R.T. for 15-20 min to dissolve the formazan dye. After gently agitation to ensure even mixture of the dye, a 96-well microplate reader (Molecular Devices) was used to determine the optical density (OD) of each well at 570 nm. Percent cell viability (CV) was determined by (treatment group OD/untreated control group OD) × 100%, using DMSO as a blank. Each assay was performed in triplicate, and repeated at least 3 times.
Drug affinity responsive target stability DARTS was performed as reported [27] [28] [29] with minor modifications. Briefly, for target identification, MDA-MB-231 cells maintained in RPMI containing 10% FBS and 1% penicillin/ streptomycin were lysed with M-PER (Pierce) with phosphatase inhibitors (50 mM NaF, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 2 mM Na 3 VO 4 ) and protease inhibitors (Roche). After lysis, cold TNC buffer (50 mM TRIS-HCl pH 8.0, 50 mM NaCl, 10 mM CaCl 2 ) was added to the lysate, and protein concentration was measured via the BCA protein assay. Lysate was incubated with either vehicle (DMSO) or varying concentrations of disulfiram for 1 h at R.T. with shaking at 600 rpm in an Eppendorf Thermomixer. The samples were then digested with different concentrations of Pronase (Roche), which is a cocktail of proteases, for 20 min at R.T. Digestion was stopped with the addition of SDS buffer, and samples were immediately heated for 10 min at 70 °C. Proteins in each sample were separated by SDS-PAGE and visualized using the ProteoSilver staining kit (Sigma). Protected bands were excised and subjected to mass spectrometry identification (Alphalyse).
For target validation, DARTS was performed as described above. Samples were separated on a 4-12% Bis-Tris gradient gel (Invitrogen), and western blotting was performed with antibodies against IQGAP1 (Cell Signaling), MYH9 (Protein Tech Group), β-actin (Cell Signaling), and GAPDH (Ambion).
Definitions of drug interaction
We used Kaspers et al. 87 model to calculate the borderlines of synergistic and additive interactions, which was developed by combining the Multiplicative 88 and Maximum 89 models for independently acting and mutually exclusive drugs, respectively. Combining these 2 models to define the type of drug-drug interaction, we get: Synergistic: the observed cell viability (CV) for a drug combination is less than the product of each single agent: observed CV(A+B) < CV(A) × CV(B) Additive: the observed CV for a drug combination is less than the max reduction in CV by either drug alone, CV(A/B max ), but is greater than the product of each single agent: CV(A) × CV(B) < observed CV(A+B) < CV(A/B max ) Antagonistic: the observed CV for a drug combination is greater than CV(A/B max ): observed CV(A+B) > CV(A/B max ).
Flow cytometry
MDA-MB-231 cells were plated at optimal densities and treated the following day with disulfiram, doxorubicin, or a combination of both. For cancer stem cell analysis: after 72 h, supernatants from each treatment group were collected before cells were trypsinized to single cell suspension. Trypsinized cells were added to their respective supernatants, washed with PBS, pelleted, resuspended in serum-free PBS, and counted. In a volume of 100 μL serum-free PBS, 0.5-1.0 × 10 6 cells were incubated with 5 μL mouse anti-human ESA/Ep-CAM/CD326-PE (BioLegend), 5 μL mouse anti-human CD24-FITC (BD Biosciences) and 5 μL mouse anti-human CD44-APC (BD Biosciences) antibody on ice, in the dark, for 30-40 min with occasional pulse vortexing. Cells were then washed and strained to single cells into 5 mL polystyrene round-bottom FACS tubes (BD Falcon) to a total volume of 500 μL (1 × 10 6 cells/mL). Finally, 5 μL 7-AAD (BD Biosciences) was added to each tube as a viability marker, and cells were processed on a FACSCaliber (Becton Dickinson) no longer than 1 h post-staining. For apoptosis analysis: after 24 or 72 h, samples were processed as above, except resuspension occurred in 1× Annexin-V binding buffer, without subsequent washing. Positive controls were achieved with a heat-shock sample (cell suspension subjected to 55 °C for 10 min prior to processing). In a volume of 100 μL 1× Annexin-V binding buffer, 0.5-1.0 × 10 6 cells were incubated with 5 μL Annexin-V-PE (BD Biosciences) in the dark, at R.T. for 15-20 min with occasional pulse vortexing. Then, 5 μL 7-AAD (BD Biosciences) and an additional 400 μL 1× Annexin V binding buffer was added to each sample. Finally, cells were strained to single cells into 5 mL polysterene round-bottom FACS tubes (BD Falcon), placed on ice, and processed on a FACSCaliber (Becton Dickinson) no longer than 1 h post-staining. Senescence-associated β-galactosidase staining MDA-MB-231 and MCF7 cells were seeded onto 6-well plates at optimal density and treated the next day with 250 nM disulfiram, 125 nM doxorubicin, or a combination of both. After 72 h, cells were washed twice with PBS, fixed with 3% formaldehyde (Sigma), and stained with X-gal/BCIG staining solution (BD Pharminogen Senescence kit) overnight at 37 °C. 90 The senescent cells (β-galactosidase-positive cells) were counted using a phase contrast light microscope and were expressed as a percentage of the total number of cells counted (minimum 500 cells counted from 4-5 plate areas).
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